Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Transcranial Magnetic Stimulation to Improve Speech in Aphasia
This study is currently recruiting participants.
Verified by National Institute on Deafness and Other Communication Disorders (NIDCD), August 2008
Sponsors and Collaborators: National Institute on Deafness and Other Communication Disorders (NIDCD)
Boston University
Harvard University
University of Pennsylvania
Information provided by: National Institute on Deafness and Other Communication Disorders (NIDCD)
ClinicalTrials.gov Identifier: NCT00608582
  Purpose

The purpose of this study is to examine whether repetitive transcranial magnetic stimulation (rTMS) can be used to improve speech in chronic stroke patients with nonfluent aphasia. Nonfluent aphasia patients have problems with speech production. The rTMS procedure allows painless, noninvasive stimulation of human cortex from outside the head.

Patients with nonfluent speech have been observed in our functional magnetic resonance brain imaging studies to have excess brain activation in brain areas possibly related to language on the right side of the brain (opposite side to where the stroke took place). It is expected that suppression of activity in the directly targeted brain region will have an overall modulating effect on the neural network for naming (and propositional speech) and will result in behavioral improvement.


Condition Intervention Phase
Nonfluent Aphasia
Broca Aphasia
Expressive Aphasia
Anomic Aphasia
Cerebrovascular Stroke
Device: Transcranial Magnetic Stimulation, Repetitive
Phase II

MedlinePlus related topics: Aphasia
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Outcomes Assessor), Parallel Assignment, Efficacy Study
Official Title: Transcranial Magnetic Stimulation to Improve Speech

Further study details as provided by National Institute on Deafness and Other Communication Disorders (NIDCD):

Primary Outcome Measures:
  • Number of pictures named on the Boston Naming Test, and naming subtests of the Boston Diagnostic Aphasia Exam [ Time Frame: 2 months and 6 months after the completion of a series of TMS treatments ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number of words per longest phrase length, propositional speech, BDAE [ Time Frame: 2 months and 6 months after completion of a series of TMS treatments ] [ Designated as safety issue: No ]

Estimated Enrollment: 90
Study Start Date: July 2002
Estimated Study Completion Date: March 2011
Estimated Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Real rTMS: Experimental
These patients receive a series of 10 Real rTMS treatments, only. There is pre-testing, and post-testing at 2 months and 6 months after the last Real rTMS treatment.
Device: Transcranial Magnetic Stimulation, Repetitive
10 rTMS treatments (90% of motor threshold, 20 minutes, at 1 Hz) to specific right hemisphere area of brain cortex; 5 days per week for 2 weeks at the Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; or at the Neurology Department, Hospital of the University of Pennsylvania, Philadelphia, PA.

Detailed Description:

OBJECTIVE: The purpose of this research is to investigate whether repetitive transcranial magnetic stimulation (rTMS) can improve speech in chronic stroke patients with nonfluent aphasia. TMS allows painless, noninvasive stimulation of brain cortex (1 cm x 1 cm). Slow (1 Hz) rTMS appears to decrease excitability in the targeted cortical region of interest (ROI) leading to measurable behavioral effects. Patients with nonfluent speech have been observed in our fMRI work (and others) to have increased activation in right (R) Broca's and other R language homologues during language tasks. It is hypothesized that suppression of activity in a directly targeted right hemisphere (RH) ROI will have an overall modulating effect on functionally connected elements of the distributed neural network for naming (and propositional speech), and will result in behavioral improvement. Patients are studied with overt naming fMRI brain scan pre-and post-rTMS at the Boston University Center for Biomedical Imaging.

RESEARCH PLAN AND METHODS:

The rTMS treatments in Boston take place at the Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School under the supervision of Alvaro Pascual-Leone, M.D., Ph.D. We plan to study 20 nonfluent aphasia patients (>6 Mo. poststroke). An additional 20 patients will be studied at the Hospital of the University of Pennsylvania, H. Branch Coslett, M.D., who is a P.I. on that subcontract. This is a blinded, randomized, sham-control, incomplete crossover design. Naming and language tests (and overt naming fMRI scans) are obtained pre- and post- rTMS. All fMRI scans are covered under the PI's VA Merit Review Grant.

Treatment Design: Multiple Baseline Language Evaluations (x3) are performed at Entry (Boston Naming Test, BNT; and Boston Diagnostic Aphasia Exam, BDAE). Primary Outcome Measures are BNT; and Naming subtests and Spontaneous Speech (cookie theft picture description) from the BDAE. Naming ability for Snodgrass & Vanderwart (S&V, 1980) pictures is also tested at Baseline. Patients are randomly assigned to receive a series of either Sham rTMS followed by a series of Real rTMS; OR they receive only the series of Real rTMS. The Sham series is identical to the Real, however, no magnetic pulse is emitted from the coil, although the patient hears the same clicking sound emitted from the coil. Due to space limitation here, only the Real rTMS treatment schedule is described.

There are two rTMS Phases: During Phase 1, the single, best RH cortical ROI to suppress with rTMS to improve picture naming, is determined for each patient. Real rTMS (1 Hz, 90% motor threshold) is applied for 10 minutes, in separate rTMS sessions, to each of 4 different RH cortical ROIs (R ant. BA 45; R post. BA 45; R BA 44 and R M1, mouth). S&V Picture Naming is tested immediately before and after each ROI has been suppressed with rTMS. The single RH ROI which is associated with at least a 2 SD improvement (above Baseline S&V Naming), immediately following 10 minutes of rTMS to suppress that cortical area, is considered to be the Best Response ROI for that patient. We have observed that suppression of R post. BA 45 to be the Best Response area in 9 previous aphasia cases. During Phase 2, the Best Response ROI from Phase 1 is suppressed for 20 minutes, 5 days per week, 2 weeks. All patients receive follow-up BNT and BDAE testing at 2 months following the 10th Real (or Sham) rTMS treatment.

  Eligibility

Ages Eligible for Study:   45 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Right Handed
  • Single, Left Hemisphere Cerebrovascular Stroke
  • Must be 6 months poststroke onset
  • Native Speaker of English
  • Clinical Diagnosis of Nonfluent Aphasia

Exclusion Criteria:

  • Intracranial metallic body from prior neurosurgical procedure
  • Implanted metallic devices: pacemaker, medication pump, vagal stimulator, deep brain stimulator, TENS unit or ventriculoperitoneal shunt
  • Past history of seizure within 1 year
  • Pregnancy
  • History of substance abuse within last 6 months
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00608582

Locations
United States, Massachusetts
VA Boston Healthcare System, Jamaica Plain Campus, Boston University Aphasia Research Center (12-A), 150 So. Huntington Ave. Recruiting
Boston, Massachusetts, United States, 02130
Contact: Paula I Martin, BS     857-364-4029     paulak@bu.edu    
Contact: Michael Ho, PhD     857-364-2213     mikeho@bu.edu    
Principal Investigator: Margaret Naeser, Ph.D.            
Berenson-Allen Center for Noninvasive Brain Stimulation, 330 Brookline Ave, Kirstein Bldg., Dept. of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School Recruiting
Boston, Massachusetts, United States, 02215
Contact: Xin Huang, BS     617-667-0256     xlhuang@bidmc.harvard.edu    
Contact: Mark Thivierge, BA     617-667-0254     mthivier@bidmc.harvard.edu    
Sub-Investigator: Alvaro Pascual-Leone, M.D., Ph.D.            
United States, Pennsylvania
Department of Neurology, Hospital of the University of Pennsylvania, 3 W. Gates Bldg. Recruiting
Philadelphia, Pennsylvania, United States, 19104-4283
Contact: H B Coslett, MD     215-349-8275     hbc@mail.med.upenn.edu    
Contact: Roy Hamilton, MD     215-349-8275     Roy.Hamilton@uphs.upenn.edu    
Sub-Investigator: H B Coslett, M.D.            
Sponsors and Collaborators
Boston University
Harvard University
University of Pennsylvania
Investigators
Principal Investigator: Margaret A Naeser, Ph.D. Department of Neurology, Boston University School of Medicine, Boston, MA
Investigator: H B Coslett, M.D. Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA
Investigator: Alvaro Pascual-Leone, M.D., Ph.D. Berenson-Allen Center for Noninvasive Brain Stimulation, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
  More Information

Aphasia Research Lab of Margaret A. Naeser, Ph.D., VA Boston Healthcare System and Dept. of Neurology, Boston University School of Medicine, Boston, MA  This link exits the ClinicalTrials.gov site
Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Dept. of Neurology, Harvard Medical School, Boston, MA  This link exits the ClinicalTrials.gov site

Publications of Results:
Responsible Party: Neurology Dept., Boston Univ. Sch. Med.; VA Boston Healthcare System, JP Campus ( Margaret A. Naeser, Ph.D. )
Study ID Numbers: NIH-DC05672, Boston Medical Ctr IRB-H22484, VA Boston Healthcare IRB-1145
Study First Received: January 24, 2008
Last Updated: August 6, 2008
ClinicalTrials.gov Identifier: NCT00608582  
Health Authority: United States: Federal Government

Keywords provided by National Institute on Deafness and Other Communication Disorders (NIDCD):
Transcranial Magnetic Stimulation, Repetitive
TMS
Treat Naming
Nonfluent Aphasia
Chronic Stroke
Randomized, Controlled Trial

Study placed in the following topic categories:
Speech Disorders
Cerebral Infarction
Aphasia
Aphasia, Broca
Stroke
Vascular Diseases
Central Nervous System Diseases
Language Disorders
Ischemia
Brain Diseases
Cerebrovascular Disorders
Anomia
Signs and Symptoms
Brain Ischemia
Neurologic Manifestations
Brain Infarction
Infarction
Neurobehavioral Manifestations
Communication Disorders

Additional relevant MeSH terms:
Nervous System Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 16, 2009